anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Blood brain barrier (BBB) breakdown is one of the key mechanisms of secondary brain injury following intracerebral hemorrhage (ICH). Astrocytes interact with endothelial and regulate BBB integrity via paracrine signaling factors. More and more studies reveal astrocyte-derived extracellular vesicles (ADEVs) as an important way of intercellular communication. However, the role of ADEV in BBB integrity after ICH remains unclear.
METHODS: ADEVs were obtained from astrocytes with or without oxygen and glucose deprivation (OGD) pre-stimulation and the role of ADEVs in ICH was investigated using ICH mice model and ICH cell model. The potential regulatory effect of ADEVs on endothelial barrier integrity was identified by TEER, western blot and immunofluorescence in vitro. In vivo, functional evaluation, Evans-blue leakage and tight junction proteins (TJPs) expression were analyzed. MiRNA sequencing revealed that microRNA-27a-3p (miR-27a-3p) was differentially expressed miRNA in the EVs from OGD-pretreated astrocytes compared with normal control. The regulatory mechanism of miR-27a-3p was assessed using Luciferase assay, RT-PCR, western blot and immunofluorescence.
RESULTS: OGD-activated astrocytes reduced hemin-induced endothelial hyper-permeability through secreting EVs. OGD-activated ADEVs alleviated BBB dysfunction after ICH in vivo and in vitro. MicroRNA microarray analysis indicated that miR-27a-3p is a major component that was highly expressed miRNA in OGD pretreated-ADEVs. OGD-ADEVs mitigated BBB injury through transferring miR-27a-3p into bEnd.3 cells and regulating ARHGAP25/Wnt/β-catenin pathway.
CONCLUSION: Taken together, these findings firstly revealed that miR-27a-3p, as one of the main components of OGD-pretreated ADEVs, attenuated BBB destruction and improved neurological deficits following ICH by regulating endothelial ARHGAP25/Wnt/β-catenin axis. OGD-ADEVs might be a novel strategy for the treatment of ICH. this study implicates that EVs from OGD pre-stimulated astrocytes.
Uveitis refers to intraocular inflammatory diseases that are an important cause of visual loss. Standard systemic immunosuppressive medications used for uveitis can cause significant toxic side effects, especially with prolonged use. Consequently, an effective treatment with a safer side effect profile is highly desirable. Daclizumab is a humanized monoclonal antibody directed against the high affinity IL-2 receptor CD25 or Tac subunit. The IL-2 receptor system plays a central role in mediating immune responses. Blocking this system impedes immune responses and can inhibit local inflammatory responses, including uveitis. Pilot studies using intravenous or subcutaneous daclizumab treatments suggest that daclizumab treatments at 1 mg/kg every 2-4 weeks for quiescent uveitis may effectively replace the other immunosuppressive medications in a majority of cases.

Because we have little experience using daclizumab for active uveitis, this feasibility study will enroll five study participants that would normally be treated with systemic, high-dose corticosteroids or other cytotoxic, systemic immunosuppressive medications. Since daclizumab for other indications can be tolerated with repeated dosing at 8-10 mg/kg, we will administer daclizumab to reach high serum levels with a pair doses at 8 mg/kg and 4 mg/kg two weeks apart. The primary objective of this study is to collect preliminary information on the utility of acute daclizumab therapy on active ocular inflammation. The primary outcome is resolution of active disease defined as the reduction of vitreous haze by at least 2 steps (from 2+ to Trace, or 1+ to none) and is assessed at 21 days after the initial daclizumab injection. Secondary outcomes will include fluorescein retinal vascular leakage, CME, anterior chamber cells, and visual acuity. In addition all adverse events will be collected regardless of possible relation to daclizumab. Participants who show a 2 step reduction in vitreous haze at day 21 will be permitted to continue SC daclizumab maintenance treatments beginning at Day 28 at 2 mg/kg every 4 weeks for a year. At any time during the followup period, if a participant loses greater than 3 lines of visual acuity from baseline study treatments will be discontinued.
The invention discloses a cold-water-fish probiotics bacillus strain and application thereof. The strain HZC58, which has anti-virus, immune adjustment and immunity enhancement characteristics for cold water fishes, is separated and identified from an intestinal tract mucous membrane of a juvenile semi-wild rainbow trout in Benxi mountainous area of Liaoning province. According to colony morphological characteristic observation, 16SrDNA base sequence determination and homology analysis, the identification result of the strain indicates that the HZC58 belongs to bacillus and the collection number is CGMCC No.10706. In-vitro cell experiments prove that the bacillus strain HZC58 is cultured together with EPCs (endothelial progenitor cells) and has the characteristic of resisting IHNV (infectious hematopoietic necrosis virus) in EPC proliferation in vitro. Animal experiments prove that the bacillus strain HZC58 has the immune adjustment and immunity enhancement characteristics for the cold water fishes, and the strain HZC58 has also the anti-virus characteristic for the cold water fishes when being used for feeding individually. The bacillus strain HZC58 has a certain application prospect in cold-water-fish anti-virus, immunity adjustment and immunity enhancement.
BACKGROUND: The effectiveness of different medical interventions in managing labor pain has yielded mixed results. Therefore, this systematic review and network meta-analysis aimed to provide a comprehensive summary of the available evidence on the impact of different strategies for reducing labor pain.
METHODS: We systematically searched 3 English databases (Pubmed, Embase and the Cochrane Library) from inception to January 2023. Randomized controlled trials (RCTs) or controlled clinical trials that investigating the effects of different strategies for reducing labor pain were included in this network meta-analysis. Risk of bias (ROB) was assessed using the Cochrane ROB tools. Network meta-analysis was performed using the R software (version 4.2.1) with gemtc package.
RESULTS: A total of 9 studies involving 823 patients, including 9 treatments (acupressure, birth ball exercise, Bonapace method, distraction techniques, ice pressure, LI4 acupressure, lidocaine spray, smartphone-based music intervention and placebo). The surface under the cumulative ranking (SUCRA) shows that Bonapace method ranked first (SUCRA, 79.5%), LI4 acupressure ranked second (SUCRA, 65.6%), distraction technique ranked third (SUCRA, 57.6%), birth ball exercise ranked fourth (SUCRA, 51.8%).
CONCLUSIONS: According to the results of the network meta-analysis, among the different strategies examined, the Bonapace Method stands out as the most effective nonpharmacological intervention for reducing labor pain. The results of this meta-analysis can aid both patients and healthcare professionals in choosing the most effective techniques to reduce labor pain.
Assessing hydration status outside of laboratories can be challenging given that most hydration measures are invasive, stationary, costly, or have questionable validity. This study investigated the within-day, test-retest reliability, and minimal detectable change (MDC) of the MX3 Hydration Testing System (MX3 Diagnostics), a relatively low cost, noninvasive, and portable method to measure saliva osmolality. Seventy-five adults (44 men, 31 women; 29.6±10.8 yr, 171.1±9.2 cm, 79.1±15.4 kg) presented two saliva samples approximately 3 to 5 minutes apart. Fluid intake was avoided for at least 5 minutes prior to sample collections. For each sample collection, a researcher used the MX3 to tap the tip of a test strip to saliva on a participant's tongue. Intra-class correlation coefficients (ICCs) and MDC were calculated as measures of reliability. Means for the two measurements were 64.3±19.0 mOsm and 65.5±17.9 mOsm (mean difference of -1.2±13.0 mOsm; t = -0.806, p = 0.423). Further analysis with a two-one-sided test procedure revealed equivalence between the two SOSM measurements (p < 0.001 for upper and lower bounds). Within-day repeat measures yielded an ICC of 0.75 and an MDC at the 90% confidence level of 21.3 mOsm. With moderate-to-good reliability, the MX3 appears to be a practical choice for reliably measuring moderate-sized changes (>20 mOsm) in saliva osmolality outside of laboratory constraints.
Participants in the WLC group will continue usual care for twelve weeks before participating in Yoga classes for eight weeks. At the end of the twelve week follow-up, these participants will receive eight weeks of group Yoga classes and the home Yoga practice recording. At week 20, they will complete a final follow-up visit.
To provide an inspection result management system, an inspection result management method, and a program for managing an inspection result.SOLUTION: In an inspection result management system, a management server 2 comprises an inspection information acquisition unit 212, an inspection information storage unit 233, a date acquisition unit 213, an expiration date determination unit 214, and an output unit 215. The inspection information acquisition unit 212 acquires a first image obtained by photographing an identification number of an inspection kit, acquires a second image obtained by photographing the end state of an inspection using the inspection kit, and acquires a result of the inspection using the inspection kit. The inspection information storage unit 233 stores the first image and second image, and the inspection result. The date acquisition unit 213 acquires the date related to the first or second image. The expiration date determination unit 214 determines the expiration date of the inspection result according to the date. The output unit 215 outputs the inspection result and the expiration date.SELECTED DRAWING: Figure 3
Taking the use of traditional Chinese medicine syndrome differentiation treatment as the exposure factor, the continuous use of traditional Chinese medicine for 3-5 days was defined as mild exposure, continuous use of traditional Chinese medicine for 6-10 days as moderate exposure, and continuous use of traditional Chinese medicine for more than 10 days as severe exposure. The exposure group was treated with syndrome differentiation of traditional Chinese medicine combined with conventional Western Medicine (treatment cohort of integrated traditional Chinese and Western Medicine).
Treatment will consist of canakinumab (ACZ885) administered as a subcutaneous injection every 3 weeks for 3 cycles concurrent with standard of care concurrent chemoradiation, followed by canakinumab administered intravenously every 4 weeks for up to 12 total infusions concurrent with standard of care durvalumab. Canakinumab (ACZ885) will be dosed at 200mg via subcutaneous injection every 3 weeks x 3 injections that will start with concurrent chemoradiation, followed by 200mg via intravenous infusion every 4 weeks x 12 infusions that will start with the initiation of durvalumab. Canakinumab (ACZ885) will be concurrent with thoracic chemoradiation and durvalumab therapy for up to 15 cycles, or until disease progression or unacceptable toxicity, whichever occurs first. Patients that come off treatment for progression, or have progression after completion of all protocol-related therapy, can be followed for survival outcomes by chart review based on standard of care evaluations.
On the first night of the study, participants can eat and drink as they normally would (no dietary intervention). On second and third nights participants will be provided meals, snacks and drinks with specific macronutrient composition, encouraged to only eat and drink study meals, snacks and drinks, and to avoid eating after 10:00 hours. The composition of the study foods and drinks on nights 2 and 3 will be different.
Recombinant TGF-beta 2 monomers engineered to prevent dimerization and block TGF-beta signaling are described. The engineered monomers lack the ability to bind and recruit TGF- βi type receptors (tβri), but retain the ability to bind high affinity TGF- βii type receptors (tβrii). TGF- β2 monomers also include additional modifications that increase their affinity for T βRII, reduce their aggregation and/or improve their folding. Nucleic acid molecules and vectors encoding recombinant TGF-beta 2 monomers are also described. Isolated cells, such as T cells, may be reprogrammed with nucleic acids or vectors encoding TGF- β2 monomers to secrete the monomer. Also described are uses of recombinant TGF-beta 2 monomers and/or cells producing recombinant TGF-beta 2 monomers for inhibiting TGF-beta signaling, e.g., for treating disorders associated with aberrant TGF-beta signaling.
INTRODUCTION: The skeletal system ranks as the third most common site for cancer metastasis, often leading to pain with nociceptive and neuropathic features. Programmed cell death protein 1 (PD-1)-targeting therapeutic antibodies offer effective cancer treatment but can cause treatment-related acute pain. Understanding the mechanisms of this pain and identifying potential interventions is still a challenge.
METHODS: A murine model of bone cancer pain was established using Lewis lung carcinoma (LLC) cells, followed by intravenous administration of nivolumab, a human anti-PD-1 monoclonal antibody. Pain thresholds were measured, and micro-CT images of the skeletal system were obtained. High-throughput sequencing of the spinal cord/colon transcriptome during the acute phase of bone cancer pain and gut microbiota analysis at the end of the treatment were performed. Immunofluorescence staining and western blot experiments assessed spinal cord microglia activation and acute pain-associated molecules.
RESULTS: PD-1 inhibition with nivolumab protected against bone degradation initiated by LLC cell administration but consistently induced acute pain during nivolumab treatment. Spinal cord and colon transcriptomics revealed an immunopathological pattern during tumor progression and the acute pain phase, with notable changes in interleukin and S100 gene families. Gut microbiota analysis post-immunotherapy showed a decline in beneficial bacteria associated with short-chain fatty acid (SCFA) production. Activation of spinal cord microglia and enhanced glycolytic metabolism were confirmed as key factors in inducing acute pain following immunotherapy.
CONCLUSIONS: This study reveals that nivolumab induces acute pain by activating microglia and enhancing glycolytic metabolism in the treatment of bone cancer and uncovers connections between transcriptomic changes, gut microbiota, and acute pain following immune checkpoint blockade (ICB) treatment. It offers novel insights into the relationship between immune checkpoint blockade therapies and pain management.
Ultra-Centrally Tumors in the Lung Ultra-centrally located tumors are tumors located within the 0.0 to 0.5 cm zone of trachea, main bronchi or intermediate bronchus. The patient will be excluded if the tumor invades the trachea, bronchi, esophagus, or pericardium/heart (radiological or by bronchoscopy assessment).
By 2025, it is estimated that approximately 1 million people in the United Kingdom (UK) will suffer from dementia, a syndrome associated with progressive decline in brain function. While there is currently no cure for most types of dementia, early diagnosis can help patients receive the appropriate treatment and support to help maintain mental function.

The focus of this project is to identify changes in retinal structure associated with dementia. In collaboration with bioinformatics experts at University College London (UCL), the investigators propose to analyse our repository of \>1 million retinal scans, termed optical coherence tomography (OCT), performed regularly on patients since 2008. OCT scans will be linked at a patient level to data from the Hospital Episode Statistics (HES) database to identify those who have been diagnosed with dementia or went on the develop dementia. Thus, a pseudonymised classified dataset of retinal scans will be generated for qualitative and quantitative analysis. The primary objective is to characterise changes in the layers of the retina associated with dementia. Machine learning techniques may also be employed to identify novel patterns of retinal change associated with dementia.
PURPOSE:To provide a hair tonic containing an S-containing diester known as an agricultural and horticultural fungicide, as an active component. CONSTITUTION:The objective hair tonic contains, as an active component, the compound of formula (R1 and R2 are lower alkyl; M is 1-2-valent inorganic or organic salt; n is 2 when M is univalent, and n is 1 when M is bivalent). The amount of the compound in the agent is 0.01-10wt%. The compounding base of the agent is e.g. an alcohol, oil or fat, surface active agent, etc., and the agent may contain other drug components such as resorcinol, hormones, vitamins, amino acids, menthol, perfumery, etc. The above hair tonic is used in the form of tonic, hair lotion, hair cream, milky lotion, shampoo, rinse, etc.
BACKGROUND AND AIMS: Several risk models for esophageal stricture after endoscopic submucosal dissection have been developed. However, some of them did not include the use of steroids in the risk analysis. Glucocorticoid sensitivity mediated by glucocorticoid receptor expression has not been discussed in this condition.
METHODS: Clinical and endoscopic characteristics were included in the logistic regression model to establish a nomogram for stenosis prediction. The score for each risk factor was estimated. Risk factors of ineffective oral steroid prophylaxis were analyzed and glucocorticoid receptor expressions were detected by immunohistochemistry.
RESULTS: Three hundred fourteen patients of endoscopic submucosal dissection for esophageal superficial neoplasms were included to develop the nomogram. The circumferential range(≤ 3/4, 3/4-1 or the whole circumference), longitudinal diameter reached 4 cm (yes or not) and lesion location (the cervical and upper thoracic part, the middle thoracic part or the lower thoracic part) consisted of the nomogram. Patients have a high risk of esophageal stricture if they have a total point greater than 36. In the simplified risk score model, the corresponding cutoff score was 1. 92 patients with oral steroid prophylaxis were separately analyzed and the circumferential mucosal defect involving 7/8 or more was an independent risk factor of ineffective prevention (OR 12.2, 95%CI 5.27-28.11). The expression of glucocorticoid receptor β was higher in the stricture group (p = 0.042 for AOD; p = 0.016 for the scoring system).
CONCLUSIONS: We established a nomogram for esophageal stricture prediction. Depending on the characteristics of lesions, it is possible to estimate the risk of stricture under routine post-ESD treatments (no steroids or oral steroids). Alternative treatments should be considered if the risk is extremely high, especially for patients with mucosal defects involving 7/8 or more of circumference in which oral steroid treatment tends to be ineffective. The higher glucocorticoid receptor β may indicate potential glucocorticoid resistance.
Compositions, methods and apparatuses for reducing or eliminating malodors from indoor air are described. The method utilizes vapor phase hydrogen peroxide (VPHP) generated from either evaporation from an aqueous-based liquid composition or sublimation from a solid hydrogen peroxide-containing compound. VPHP engages a media coated with at least one transitional metal element or compound, which acts as an oxidation catalyst, in the presence of air that contains malodorous compounds to provide increased efficacy of malodor molecule oxidation. The apparatus can employ a disposable porous non-woven filter pad coated with one or more transition metal compounds, and a solid source of VPHP. Malodor-containing air engages the pad in the presence of the VPHP to effectively oxidize the malodorants. The apparatus can also include a mechanism to provide color change(s) in the presence of VPHP to indicate whether the device contains VPHP or not.
The invention provides a compound modified chitin gel preparation and a preparation method thereof, belonging to the field of pharmaceutical preparations. Specifically, the compound modified chitin gel preparation comprises two active ingredients of local anesthetic and chitosan and pharmaceutically acceptable auxiliary materials. The auxiliary materials comprise: gel matrix, pH regulator composed of acid and alkali, solubilizer, humectant, and solvent. The gel of the invention can stop bleeding and relieve pain, is convenient for patients to use, has no foreign body sensation, and can greatly improve the compliance of the patients. The gel of the invention can sterilize and disinfect, promote the activation of cells, generate a large amount of collagen fibers, prevent wounds from leaving scars and promote the healing of wound surfaces. The gel has good biocompatibility and biodegradability, and has strong bacteriostatic and wound healing promoting effects.
FIELD: medicine, veterinary science, pharmaceutical industry. SUBSTANCE: invention relates to development of novel medicinal agents. The proposed preparation comprises at least one placenta extract, at least one derivative of nucleic acid and at least one vitamin. Nucleic acid sodium salt or ridostin can be used as nucleic acid derivative and vitamin C or vitamins of group B can be used as vitamin. Preparation can comprise additionally at least one amino acid. Medium 199 or medium RPMI 1640 or another medium used for mammalian cell culturing and comprising vitamins and amino acids can be used as source of vitamins and amino acids. EFFECT: expanded assortment of drugs showing broad spectrum effect. 6 cl, 10 tbl
The process comprises the preparation of pharmaceutical and cosmetic compositions from biological active substances. These active substances are extracted from the plant raw materials using milk serum with particular temperatures and times, and are purifed. Milk serum containing the active substances from medicinal herbs can, because milk serum is simultaneously emulsifier and steriliser, be used for the preparation of O/W or W/O emulsions. Plant fats and oils are mainly used for the preparation of creams and ointments. Milk serum extracts of medicinal herbs can be blended with fruit juices, vegetable juices, mineral water etc. In addition, milk serum extracts of medicinal herbs are used for the preparation of medicinal and cosmetic articles.
Pos4Health is a 6 Core Internet intervention focusing on improving adherence to ART among nonadherent substance users living with HIV in non urban areas. Pos4Health Cores each present a topic, show videos of HIV+ peers discussing that topic, and how they have coped with it, and use interactions to teach about the topic and to develop knowledge and skills. Each core ends with tips to try that include tips mentioned by peers or from expert material. Content is personalized to the user and users receive tailored feedback. Cores are metered out weekly after each Core is completed.